Why the study?
Despite increasing data demonstrating the clinical safety and efficacy of transcatheter tricuspid valve interventions, uncertainties remain regarding optimal case selection and procedural timing.
Transcatheter tricuspid valve interventions are emerging as a low-risk alternative to surgery for high-risk patients with tricuspid regurgitation.
TR prevalence and poor prognosis in elderly patients warrant renewed therapeutic focus; leaves open effective nonsurgical options.
Tricuspid regurgitation (TR) has a community prevalence of 3%, which increases with age and affects up to 7% of elderly patients. TR is secondary (functional) in 90% of cases (usually resulting from left heart disease and/or pulmonary hypertension), although atrial dilatation is an increasingly recognised cause. Awareness of the poor prognosis associated with increasing TR severity has refocused the quest for effective treatments. Surgical intervention has been hindered by high in-hospital mortality (up to 10%), even in carefully selected cases, and transcatheter tricuspid valve interventions (TTVIs) have emerged as a low-risk alternative for this high-risk cohort. Increasing data demonstrate the clinical safety and efficacy of TTVIs, but uncertainties remain concerning optimal case selection and procedural timing. Herein, we review newly established techniques alongside emerging clinical and procedural outcome data.
No takes yet. Share an insight, caveat, or question.
Wilcox et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: